In a perfect world, every framework developer would follow guiding practices to ensure they are using sound methodology and evidence, meaningfully incorporating patient input, and considering a broad array of benefits and costs over a longer timeframe, as outlined in NPC's "Guiding Practices for Patient-centered Value Assessment" and highlighted in this blog post.

A white paper from NPC and Discern Health analyzes the landscape of available patient-reported measures and patient-reported performance measures in oncology, and offers recommendations for filling gaps in measures and removing barriers to measure implementation in accountable care programs.

In his latest column for Specialty Pharmacy Times, NPC President and CEO Dan Leonard explores recent research that found biopharmaceuticals provide substantial health care benefits at modest cost for six of the top seven conditions causing death and mortality between 1995 and 2005, providing powerful proof with which to challenge the conventional wisdom that all health care spending is out of control.